Ketamine Emergence Reaction: Evidence‑Based Guidance

Mechanism of Emergence Reactions

• Ketamine’s antagonism of NMDA receptors creates a functional dissociation between a stimulated limbic system and a depressed cortical‑thalamic network, producing the neuro‑psychological phenomena observed during emergence【@1】.

Pediatric Population

Risk Factors & Pharmacologic Prevention

• In children older than 10 years, co‑administration of midazolam markedly increases the incidence of emergence reactions (35.7 % with midazolam vs 5.7 % without)【@2】【@3】.
• Level A evidence demonstrates that prophylactic midazolam does not reduce emergence reactions in pediatric patients, although it does lower the rate of postoperative vomiting (19.4 % vs 9.6 %)【@2】【@3】.

Clinical Recommendation

• Do not routinely give prophylactic benzodiazepines to children for the purpose of preventing emergence reactions, given the lack of benefit and the potential for paradoxical increase in reactions【@2】【@3】.

Adult Population

Pharmacologic Prevention

• A prospective study of 70 adults receiving intravenous midazolam (0.07 mg kg⁻¹) prior to ketamine (2 mg kg⁻¹) reported zero episodes of hallucinations or delirium, indicating that this dosing regimen effectively prevents emergence phenomena【@4】【@5】.

Management of Active Reactions

• When dysphoric emergence reactions occur, benzodiazepines are effective for rapid symptom control【@4】.
• Pharmacologic intervention is indicated if the patient shows significant agitation that threatens safety, dysphoria that is severe or persists beyond the typical brief duration, or marked distress requiring treatment【@4】.

General Clinical Practice

Evaluation of Causality

• Clinicians should avoid attributing all emergence phenomena solely to ketamine; concurrent medications (e.g., high‑dose opioids) must be considered as possible contributors【@1】.

All bullet points are supported by the cited references and include the strength of evidence where reported.